S tereotactic radiosurgery (SRS) delivers focused radiation from the decay of cobalt-60 in a single, minimally invasive procedure. The application of SRS is of interest in patients with medically refractory trigeminal neuralgia (TN) since it is considered the least invasive procedure for patients with associated comorbid conditions. 11 The radiobiological effect of radiation is dependent on the amount of energy delivered (known as the integral dose [ID]) 1 to the intended target. ID is the product of the mean dose and the target volume. 10 Therefore, when the prescribed radiation target dose and treatment volume remain constant, the energy delivered to the tissue will increase proportionally to the volume of tissue within that target volume. For SRS in patients with TN, the treatment volume is usually an oblate spheroid (enclosing a segment of nerve and adjacent cerebrospinal fluid) and defined by the ABBREVIATIONS BNI-NS = Barrow Neurological Institute Numbness Scale; BNI-PS = BNI Pain Scale; CI = confidence interval; HR = hazard ratio; ID = integral dose; SRS = stereotactic radiosurgery; TN = trigeminal neuralgia. OBJECTIVE During the last 25 years, more than 100,000 patients worldwide with trigeminal neuralgia (TN) have undergone stereotactic radiosurgery (SRS) with a standard dose of radiation. However, the radiobiological effect of radiation is determined by the amount of energy delivered to the tissue (integral dose [ID] = mean dose × target volume) and is directly associated with the nerve volume. Although the trigeminal nerve volume varies among patients with TN, the clinical impact of this variation in delivered energy is unknown. The objective of this study was to evaluate the effect of delivered ID on the outcome of TN radiosurgery. METHODS The authors evaluated 155 patients with unilateral TN who had undergone SRS as their initial surgical management over a 13-year period. The authors measured the postganglionic ID within the SRS target and retrospectively stratified patients into 3 groups: low (< 1.4 mJ), medium (1.4-2.7 mJ), and high (> 2.7 mJ) ID. Clinical outcomes, which included pain status (scored using the Barrow Neurological Institute Pain Scale) and sensory dysfunction (scored using the Barrow Neurological Institute Numbness Scale), were evaluated at a median follow-up of 71 months. RESULTS Patients who were treated with a medium ID had superior pain relief either with or without medications (p = 0.006). In the medium ID group, the rates of complete pain relief without medications at 1, 3, and 6 years after SRS were 67%, 54%, and 33%, respectively, while the rates in the rest of the cohort were 55%, 36%, and 19%, respectively. Patients given a high ID had a higher rate of post-SRS trigeminal sensory deterioration (p < 0.0001). At 1, 3, and 6 years after SRS, the high ID group had an estimated rate for developing sensory dysfunction of 35%, 45%, and 50%, respectively, while the rates in patients receiving low and medium IDs were 3%, 4%, and 9%, respectively. The optimal clinical outcome (maximum pain relief and minimal trigeminal sensory dysfunction) was obtained in patients who had received a medium ID. CONCLUSIONS With current dose selection methods, nerve volume affects long-term clinical outcomes in patients with TN who have undergone SRS. This study suggests that the prescribed SRS dose should be customized for each TN patient based on the nerve volume. https://thejns.org/doi/abs/Proposed radiosurgical planning for trigeminal neuralgia J Neurosurg Volume 128 • February 2018 453 1 yr 67% (57%−77%) 56% (45%−68%) 3 yrs 62% (51%−72%) 39% (28%−50%) 6 yrs 49% (36%−61%) 23% (11%−35%) Boldface type indicates statistical significance. * Mantel-Cox log-rank test. Proposed radiosurgical planning for trigeminal neuralgia J Neurosurg Volume 128 •
4-mm collimator of the Leksell Gamma Knife. Although the trigeminal nerve volume varies among patients, the relationship between the ID delivered and clinical outcomes (defined as pain control and trigeminal sensory dysfunction) has not been studied. In this report, we evaluated the relationship between energy delivered and clinical outcomes in patients with TN who had undergone SRS as their initial surgical procedure over a 13-year period.
Methods

Patients
Between January 2002 and December 2014, 302 patients with unilateral medically refractory TN had undergone SRS as their initial surgical procedure. For this retrospective study, we excluded patients with atypical TN, patients who were unable to undergo MRI for target selection, patients with intracranial tumors that compressed the trigeminal nerve, patients with a follow-up less than 12 months, and patients with preexisting trigeminal sensory loss. The final study included 155 patients (mean age 71 years, 95% CI 69-72 years), 57 males and 98 females. Patient follow-up information was collected from medi-cal records available in our system and supplemented by direct follow-up contact with the patient by a member of our team who was not involved in the patient's care. Pain outcomes were assessed using the Barrow Neurological Institute Pain Scale (BNI-PS), 4 in which a score of I is defined as no pain on no medication, II as occasional pain but not requiring medication, III as no pain but on medication, IV as residual pain not adequately controlled with medication, and V as refractory pain without benefit from medication. Trigeminal sensory loss after SRS was evaluated using the BNI Numbness Scale (BNI-NS), 4 in which a score of I is defined as no trigeminal sensory loss, II as mild but not bothersome trigeminal sensory loss, III as bothersome trigeminal sensory loss, and IV as very bothersome trigeminal sensory loss. The University of Pittsburgh approved our protocol for this retrospective study. Patient preradiosurgical demographic information is shown in Table 1 .
Procedures
SRS had been performed as described previously. 8 All procedures were performed with a model G Leksell ste- reotactic frame (Elekta Instruments) and either the C, 4C, or Perfexion Gamma Knife. All patients underwent axial gadolinium-enhanced MRI using a 512 × 256 matrix with 1-mm slice thickness and whole-head, 3-mm, axial T2weighted imaging. Most patients also underwent axial 3D fast spin echo, 1-mm slice thickness T2-weighted MRI. Acquired images were exported to Leksell Gamma Knife computers, and a dose plan was created using the Leksell Gamma Plan. A 4-mm collimator was used to deliver the target dose (median dose was 80 Gy at the 100% isodose) for radiosurgical planning. The nerve volume inside the 50% isodose volume of the 4-mm isocenter was contoured retrospectively using stereotactic T1-weighted MRI studies obtained at the time of SRS. Accordingly, the minimum dose, maximum dose, and ID (mean dose × tissue volume) inside the 50% isodose line were calculated using dose-volume histograms as shown in Fig. 1 . The mean nerve volume covered by the 50% isodose line was 31.3 mm 3 (95% CI 29.3-33.2 mm 3 ), while the median was 31.6 mm 3 . Patients were further divided into 3 groups based on the ID inside the 50% isodose line that they had received: low (n = 33, ID < 1.4 mJ), medium (n = 79, ID 1.4-2.7 mJ), and high (n = 43, ID > 2.7 mJ) ID groups. The nerve volume inside the 50% isodose line was used to calculate the ID (energy received by the target). The correlation between nerve volume and ID is shown as a scatterplot in Fig. 1 . The ID was then correlated with pain outcomes and trigeminal nerve sensory dysfunction.
Nerve Correlation Studies
A subset of patients' nerves (n = 68), selected based on imaging availability, were further analyzed to determine the validity of using the 50% isodose nerve volume as a surrogate for the total cisternal nerve volume. Using the cisternal component of the treated nerve as outlined from the brainstem root entry point to the opening of Meckel's cave as our boundaries, we determined the total cisternal nerve volume and the respective ID delivered. Further, we measured the length of the cisternal component of each nerve. With these additional parameters, we performed a series of correlational analyses to assess the relationship between which specific anatomical parameters (50% isodose line volume vs cisternal nerve volume vs cisternal nerve length) correlated best with ID delivered (to the 50% isodose tissue vs to the cisternal nerve tissue).
Statistical Analysis
Any statistical comparison was considered significant if the p value was less than 0.05. Patient pain relief (preservation of BNI-PS Scores I-III) and trigeminal sensory dysfunction (BNI-NS score > I) outcome analyses were performed using the Kaplan-Meier approach. All confidence intervals (CIs) were calculated using the Greenwood method and quoted as 95% limits for each estimate referenced in the results and/or tables. Comparisons between groups (low, medium, and high ID groups) were performed using the Mantel-Cox log-rank test for Kaplan-Meier analysis. Continuous variables (patient age, SRS dose parameters, follow-up duration, duration of pre-SRS symptoms, and nerve volume) were compared using the Wilcoxon ranksum test. Comparison of patient sex and pain side (right vs left) within each group was done using the Fisher exact test. Cox proportional hazards regression models were used to elucidate potential contributors to the development of BNI-NS scores > I and to the post-SRS deterioration of BNI-PS Scores I and I-III. To assess the development of BNI-NS scores > I, a Cox proportional hazards regression analysis with a stepwise selection procedure was performed to identify significant covariates using the following variables: age (continuous), sex (male vs female), duration of preradiosurgical pain (continuous), pain side (right vs left), and SRS dose parameters (mean dose in 50% isodose line, minimum dose in 50% isodose line, maximum dose in 50% isodose line, margin dose, and maximum dose received by brainstem; all continuous). A non-stepwise Cox proportional hazards regression analysis was then performed to examine the relationship between nerve ID and the development of BNI-NS scores > I, while adjusting for those significant covariates identified by the stepwise procedure. Nerve ID was categorized into 3 groups (low, medium, and high), and the medium group was used as the referent group. To assess the risk of BNI-PS Scores I and I-III deterioration, a forward stepwise Cox proportional hazards regression analysis was performed using the following variables: age (continuous), sex (male vs female), duration of preradiosurgical pain (≤ 3 vs > 3 years), pain side (right vs left), development of post-SRS trigeminal sensory dysfunction (presence vs absence), and SRS dose parameters (mean dose in 50% isodose line, minimum dose in 50% isodose line, and maximum dose in 50% isodose line, margin dose, and maximum dose received by brainstem; all continuous). A non-stepwise Cox proportional hazards regression analysis was then performed with the variables deemed significant from the aforementioned forward stepwise analyses alongside patient nerve ID using the medium nerve ID as a reference. All hazard ratios (HRs) are reported with 95% CIs. The relationship between trigeminal nerve volume and ID delivered to the target tissue within the 50% isodose line was demonstrated using a scatterplot of patient nerve volume versus ID; the Pearson correlation coefficient (r 2 ) was quoted for degree of curve linearity. Correlational studies between ID, nerve volume, and nerve length were performed using Pearson and Spearman correlation coefficients.
Results
To assess factors associated with superior pain relief, we performed an initial stepwise forward Cox proportional hazards regression analysis and identified earlier SRS (≤ 3 years from diagnosis) as the only predictive factor (p < 0.0001). Using a non-stepwise Cox proportional hazards regression, we found that earlier treatment (p < 0.0001) was a positive predictor of pain relief, while low ID (p = 0.011) and high ID (p = 0.005) were negative predictors of pain relief ( Table 2 and Fig. 2A ). After SRS, patients who had received a medium ID experienced superior pain relief either with or without medications (p = 0.006; Fig.  2A-D) . At follow-ups of 1, 3, and 6 years after SRS, the medium ID group had the highest rate of complete pain relief without medications: 67% (95% CI 57%-77%), 54% (95% CI 43%-65%), and 33% (95% CI 21%-44%), respectively. The remainder of the cohort had estimated rates of complete pain relief without medication of 55% (95% CI 44%-66%), 36% (95% CI 25%-47%), and 19% (95% CI 9%-29%) at the 1-, 3-, and 6-year follow-ups, respectively. Details of the pain outcomes are outlined in Table 3 .
To identify factors associated with trigeminal sensory dysfunction, we performed an initial stepwise forward Cox proportional hazards regression analysis and found that increased ID (p = 0.002) was predictive of trigeminal sensory dysfunction. However, in a non-stepwise Cox proportional hazards regression analysis, high ID (p < 0.0001) was the only predictor of trigeminal sensory loss development ( Table 2 and Fig. 2E ). Patients with a high ID (> 2.7 mJ) had a higher rate of post-SRS trigeminal sensory deterioration (p < 0.0001; Fig. 2F ) than patients in the low and medium ID groups. At 1, 3, and 6 years after SRS, the
FIG. 2. Association between ID and clinical outcome. A:
Cox proportional HRs for the 3 ID groups (low, medium, high) were plotted using the medium ID (1.4-2.7 mJ) as a reference group that was set to an HR of 1.00 for complete pain control without medications. B: Kaplan-Meier analysis of post-SRS rates of complete pain control without medications for the medium ID group (green) versus the rest of the population (red) (p = 0.006, Mantel-Cox log-rank test). C: Cox proportional HRs for the 3 ID groups were plotted using the medium ID as a reference group that was set to an HR of 1.00 for complete pain control with medications. D: Kaplan-Meier analysis of post-SRS rates of complete pain control with medications for the medium ID group (green) versus the rest of the population (red) (p = 0.006, Mantel-Cox log-rank test). E: Cox proportional HRs for the 3 ID groups were plotted using the medium ID as a reference group that was set to an HR of 1.00 for normal sensory function deterioration risk. high ID group had an estimated rate for developing sensory dysfunction of 35% (95% CI 21%-49%), 45% (95% CI 30%-60%), and 50% (95% CI 35%-65%), respectively. Development of trigeminal sensory dysfunction at 1, 3, and 6 years post-SRS in patients who had received a low or medium ID was 3% (95% CI 0%-6%), 4% (95% CI 0%-8%), and 9% (95% CI 2%-15%), respectively ( Table  4 ). Two patients within the high ID group developed deafferentation pain after SRS.
A schematic of the relationship between ID and clinical outcome is depicted in Fig. 3 left. Using a quadratic Cox regression model with target ID as a continuous variable, we determined that an ID between 1.4 and 2.7 mJ was the optimum range for best pain relief with the least risk of sensory loss. To optimize the mean dose selection for best outcomes for any nerve volume, we generated a hypothetical ID curve to optimize outcomes (Fig. 3 right) .
Finally, the degree of correlation between the 50% isodose line and its respective ID was the strongest of all correlation analyses performed (Pearson r 2 = 0.994, p < 0.0009). The degree of correlation between the trigeminal nerve cisternal volume and its respective ID demonstrated a strong correlation as well (Pearson r 2 = 0.919, p < 0.0009). The total nerve length demonstrated the least correlational relationship with ID delivered to the 50% isodose tissue (Pearson r 2 = 0.441, p < 0.0009) as well as with the total cisternal nerve tissue (Pearson r 2 = 0.475, p < 0.0009). Figure 4 and Table 5 display all correlations that were assessed regarding ID and nerve metric parameters.
Discussion
More than 60 years ago, Mayneord introduced the concept of ID, 10 which was defined as the total energy absorbed by the target volume of tissue (tissue volume × mean dose it receives). By definition, if the radiation dose remains constant, ID increases as the radiated target volume increases. More importantly, the desired effect and the risks of radiation depend on ID. 2 SRS is a widely used method to precisely deliver focused radiation and has been applied to more than 100,000 TN patients worldwide. 11, 13, 17 Given its minimally invasive nature, it is now considered to be a primary option for management of TN in patients who are poor surgical candidates. 11 SRS exerts its radiobiological effect on the trigeminal nerve by axonal and myelin sheath damage and destruction of ionic channels, resulting in a blockade of electrical conduction. 6, 14 The radiation dose that leads to sufficient pain control is considered to be the best therapeutic dose. However, when the radiobiological damage results in major axonal damage, it is likely that patients will also develop trigeminal neuropathy.
In the current study, we found that the delivered ID varies substantially (varying by as much as a factor of 10) depending on the volume of the trigeminal nerve that is irradiated. We demonstrated that the target ID plays a significant role in long-term clinical outcomes after SRS. Our results show that by evaluating the trigeminal nerve target
FIG. 3. Left:
Relationship between ID and clinical outcome. The white area reflects 33 patients who had received an ID < 1.4 mJ, the green area reflects 79 patients who had received an ID between 1.4 and 2.7 mJ, and the red area reflects 43 patients who had received an ID > 2.7 mJ. The relative outcome of each group is depicted adjacent to each area. The best outcome (good pain relief and limited sensory loss) was noted for the medium ID group. Right: Hypothetical mean dose range, depending on the trigeminal nerve target volume, for best clinical outcomes based on optimum ID (lower limit: blue; upper limit: red). Figure is available in color online only. volume and adjusting the delivered dose, pain relief can be achieved with a low risk of additional trigeminal sensory loss. In fact, in this study, trigeminal sensory loss was not associated with pain relief after SRS, whereas controversial results (sensory loss was associated with better pain relief) are reported in prior studies. 5, 7, 9, 12, 16 This divergence of opinion may be related, in part, to the heterogeneity of the study cohorts. For example, the majority of patients enrolled in prior studies underwent SRS as their second or third surgical procedure. In contrast, the present study evaluated only patients without prior surgery. All patients had received a standard maximum target dose of 80-85 Gy to the trigeminal target in a single outpatient procedure. We found that patients with a larger postganglionic nerve volume (and who received a higher ID) had a higher risk of developing trigeminal neuropathy without improving pain relief. This finding is supported by our previously published, prospective, randomized, double-blinded study, in which we found that a larger volume of radiated postganglionic nerve (and therefore higher ID) led to increased sensory loss but no improvement in pain outcome. 3 Moreover, in a recent study by Senova et al., patients with vestibular schwannoma who received a higher ID delivered to the trigeminal nerve were more likely to develop trigeminal neuropathy. 15 To maximize pain control while minimizing the risk of sensory loss, data in the current study suggest that the prescribed dose should be carefully tailored to the volume of the nerve in individual patients to optimize the ID delivered. Lastly, the current study demonstrates the utility of using the 50% isodose line ID as a surrogate for the total ID delivered to the total cisternal nerve volume, thereby supporting the use of the 50% isodose line ID as a potential prognostic index for post-SRS pain relief and trigeminal sensory dysfunction. In the future, a prospective trial that optimizes ID may provide a higher level of scientific evidence. Such a trial is currently under consideration by the International Gamma Knife Research Foundation.
Conclusions
In order to maximize pain control while minimizing the risk of sensory loss, the prescribed dose should be carefully tailored to the volume of the nerve enclosed in the 50% isodose volume, leading to a delivered ID of 1.4−2.7 mJ.
